This is a working overview of Cyclic AMP, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-14. Anything still debated is marked as such rather than presented as settled.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
== History == BioDuro was founded in 1996 in the United States as a drug discovery services company. In 2009, it was acquired by Pharmaceutical Product Development (PPD), a leading global contract research organization. In 2020, Advent International merged BioDuro with the China-based CRO Sundia to form BioDuro-Sundia, creating a combined CRDMO serving biotech and pharma clients globally. In 2021, the company expanded its U.S. operations in Irvine to support clinical and commercial drug product manufacturing. In 2025, BioDuro announced new investments in China, including a Bengbu process development and scale-up site and an OEB-5 high-potency laboratory for ADC payloads and HPAPIs.
== Pathophysiology == Dupuytren’s contracture is a fibroproliferative disorder of the palmar fascia in which abnormal activation of fibroblasts and myofibroblasts, driven by mediators such as transforming growth factor-beta, platelet-derived growth factor, epidermal growth factor, interleukin-1 beta, and connective tissue growth factor, leads to excess deposition of type III collagen and progressive remodeling of fascial tissue. Studies have suggested that intracellular signaling, as opposed to paracrine or endocrine signaling, may be the strongest driver of abnormal fibroblast activity in most cases of Dupuytren's contracture. The disease typically evolves through a proliferative stage marked by cellular nodules rich in immature fibroblasts and myofibroblasts, an involution stage in which these cells align along longitudinal stress lines in the hand, and a residual stage in which dense, relatively hypocellular collagenous cords persist and mechanically flex the digits. As normal fascial structures are converted into pathologic cords, characteristic deformities emerge: central cords commonly produce skin puckering and metacarpophalangeal contracture, natatory cords (developed from the natatory ligament) narrow the web spaces, and spiral cords can cause proximal interphalangeal contracture while displacing the digital neurovascular bundle.
On June 11, 2013, just days after being robbed at gunpoint in San Francisco, rapper 2 Chainz was arrested at Los Angeles International Airport on charges of possessing promethazine and codeine syrup (the primary ingredient of lean) along with marijuana. Mac Miller, who died of a drug overdose not involving lean, spoke openly of his addiction to lean. On April 7, 2015, Swedish rapper Yung Lean, while living in Miami Beach, Florida, and recording his second studio album Warlord, was hospitalized at Mount Sinai Medical Center due to an overdose stemming from an addiction to Xanax, cocaine, and lean. On November 26, 2024, rapper Lil Shine was charged with attempting to acquire controlled substances, after he and two others were accused of hacking into the Drug Enforcement Administration’s physicians system to acquire large amount of promethazine and codeine (the main ingredients in lean) with the intent to sell them.
In the first total synthesis in 1936, ethyl 3-ethoxypropanoate was treated with ethyl formate to give an intermediate dicarbonyl compound which when reacted with acetamidine formed a substituted pyrimidine. Conversion of its hydroxyl group to an amino group was carried out by nucleophilic aromatic substitution, first to the chloride derivative using phosphorus oxychloride, followed by treatment with ammonia. The ethoxy group was then converted to a bromo derivative using hydrobromic acid. In the final stage, thiamine (as its dibromide salt) was formed in an alkylation reaction using 4-methyl-5-(2-hydroxyethyl)thiazole.
== Synaptic plasticity == AMPA receptors (AMPAR) are both glutamate receptors and cation channels that are integral to plasticity and synaptic transmission at many postsynaptic membranes. One of the most widely and thoroughly investigated forms of plasticity in the nervous system is known as long-term potentiation (LTP). There are two necessary components of LTP: presynaptic glutamate release and postsynaptic depolarization. Therefore, LTP can be induced experimentally in a paired electrophysiological recording when a presynaptic cell is stimulated to release glutamate on a postsynaptic cell that is depolarized. The typical LTP induction protocol involves a "tetanus" stimulation, which is a 100-Hz stimulation for 1 second. When one applies this protocol to a pair of cells, one will see a sustained increase of the amplitude of the excitatory postsynaptic potential (EPSP) following tetanus. This response is interesting because it is thought to be the physiological correlation for learning and memory in the cell. In fact, it has been shown that, following a single paired-avoidance paradigm in mice, LTP can be recorded in some hippocampal synapses in vivo. The molecular basis for LTP has been extensively studied, and AMPARs have been shown to play an integral role in the process. Both GluR1 and GluR2 play an important role in synaptic plasticity.
Sources: en.wikipedia.org
Chelation therapy is a form of medical treatment in which a chelating ligand is used to selectively remove a metal from the body. When the metal exists as a divalent ion, such as with lead, Pb2+ or mercury, Hg2+ selectivity against calcium, Ca2+ and magnesium, Mg2+, is essential in order that the treatment does not remove essential metals. Selectivity is determined by various factors. In the case of iron overload, which may occur in individuals with β-thalessemia who have received blood transfusions, the target metal ion is in the +3 oxidation state and so forms stronger complexes than the divalent ions. It also forms stronger complexes with oxygen-donor ligands than with nitrogen-donor ligands. deferoxamine, a naturally occurring siderophore produced by the actinobacter Streptomyces pilosus and was used initially as a chelation therapy agent. Synthetic siderophores such as deferiprone and deferasirox have been developed, using the known structure of deferoxamine as a starting point. Chelation occurs with the two oxygen atoms. Wilson's disease is caused by a defect in copper metabolism which results in accumulation of copper metal in various organs of the body. The target ion in this case is divalent, Cu2+. This ion is classified as borderline in the scheme of Ahrland, Chatt and Davies. This means that it forms roughly equally strong complexes with ligands whose donor atoms are N, O or F as with ligands whose donor atoms are P, S or Cl.
== Honours == Hird jointly won the Brownlow Medal with Michael Voss in 1996, the award for the fairest and best player in the Australian Football League. After his retirement, Hird stated that being a member of the "Brownlow Club" was a privilege. In 1997, the Essendon Football Club named the then-triple best and fairest winner in its Team of the Century on the half-forward flank. In 2002, the Essendon Football Club conducted a fan-voted promotion to find the "Champions of Essendon". Hird was eventually named as the number three player on the all-time list of Essendon players.
== Strategies to limit drug prices in the United States == In the United States there are many resources available (to both state and local governments, and to patients directly) to lower the price patients must pay for medications; such costs can include copayments, coinsurance, and deductibles. The Medicaid Drug Rebate Program is one example. Generic drug programs lower the amount of money patients have to pay when picking up their prescription at the pharmacy. As their name implies, they only cover generic drugs. Co-pay assistance programs are programs that help patients lower the costs of specialty medications; i.e., medications that are on restricted formularies, have limited distribution, and/or have no generic version available. These medications can include drugs for HIV, hepatitis C, and multiple sclerosis. Patient Assistance Program Center (RxAssist) has a list of foundations that provide co-pay assistance programs. Co-pay assistance programs are for under-insured patients. Patients without insurance are not eligible for this resource; however, they may be eligible for patient assistance programs. Patient assistance programs are funded by the manufacturer of the medication. Patients can often apply to these programs through the manufacturer's website. This type of assistance program is one of the few options available to uninsured patients. The out-of-pocket cost for patients enrolled in co-pay assistance or patient assistance programs is $0.
Intensity-fading MALDI is a term coined to rename an existing method originally reported in 1999 to indirectly study a Protein–protein interaction or other protein complex and was the same year applied to a biological mixture to study the antigenicity of the influenza virus. It involves treating a protein and a potential binding partner with a site-specific endoproteinase with the binding sites identified by their reduced area (or intensity) in a MALDI mass spectrum compared to that of non-bound protein control. It was falsely reported as new and novel in a later application by a Spanish group. The true origins of the approach and a range of applications including those employing gel based separations, drug-protein interactions and the relative affinity of such interactions, are described in a review article.
Sources: en.wikipedia.org
The authors demonstrated that it is possible to switch the wettability behaviour of the cellulose surfaces between super-wetting and super-repellent, using different scales of roughness and porosity created by the freeze-drying technique and change of concentration of the nanocellulose dispersion. Structured porous cellulose foams can however also be obtained by utilizing the freeze-drying technique on cellulose generated by Gluconobacter strains of bacteria, which bio-synthesize open porous networks of cellulose fibers with relatively large amounts of nanofibrils dispersed inside. Olsson et al. demonstrated that these networks can be further impregnated with metalhydroxide/oxide precursors, which can readily be transformed into grafted magnetic nanoparticles along the cellulose nanofibers. The magnetic cellulose foam may allow for a number of novel applications of nanocellulose and the first remotely actuated magnetic super sponges absorbing 1 gram of water within a 60 mg cellulose aerogel foam were reported. Notably, these highly porous foams (>98% air) can be compressed into strong magnetic nanopapers, which may find use as functional membranes in various applications.
=== EC 2.4.1: Hexosyltransferases === EC 2.4.1.1: Glycogen phosphorylase EC 2.4.1.2: dextrin dextranase EC 2.4.1.3: deleted, included in EC 2.4.1.25 EC 2.4.1.4: amylosucrase EC 2.4.1.5: dextransucrase EC 2.4.1.6: deleted EC 2.4.1.7: sucrose phosphorylase EC 2.4.1.8: maltose phosphorylase EC 2.4.1.9: inulosucrase EC 2.4.1.10: levansucrase EC 2.4.1.11: glycogen(starch) synthase EC 2.4.1.12: cellulose synthase (UDP-forming) EC 2.4.1.13: sucrose synthase EC 2.4.1.14: sucrose-phosphate synthase EC 2.4.1.15: α,α-trehalose-phosphate synthase (UDP-forming) EC 2.4.1.16: chitin synthase EC 2.4.1.17: glucuronosyltransferase EC 2.4.1.18: ,4-α-glucan branching enzyme EC 2.4.1.19: cyclomaltodextrin glucanotransferase EC 2.4.1.20: cellobiose phosphorylase EC 2.4.1.21: starch synthase EC 2.4.1.22: lactose synthase EC 2.4.1.23: sphingosine β-galactosyltransferase EC 2.4.1.24: 1,4-α-glucan 6-α-glucosyltransferase EC 2.4.1.25: 4-α-glucanotransferase EC 2.4.1.26: DNA α-glucosyltransferase EC 2.4.1.27: DNA β-glucosyltransferase EC 2.4.1.28: glucosyl-DNA β-glucosyltransferase EC 2.4.1.29: cellulose synthase (GDP-forming) EC 2.4.1.30: 1,3-β-oligoglucan phosphorylase EC 2.4.1.31: laminaribiose phosphorylase EC 2.4.1.32: glucomannan 4-β-mannosyltransferase EC 2.4.1.33: mannuronan synthase EC 2.4.1.34: 1,3-β-glucan synthase EC 2.4.1.35: phenol β-glucosyltransferase EC 2.4.1.36: α,α-trehalose-phosphate synthase (GDP-forming) EC 2.4.1.37: fucosylgalactoside 3-α-galactosyltransferase EC 2.4.1.38: β-N-acetylglucosaminylglycopeptide β-1,4-galactosyltransferase EC 2.4.1.39: steroid N-acetylglucosaminyltransferase EC 2.4.1.40: glycoprotein-fucosylgalactoside α-N-acetylgalactosaminyltransferase EC 2.4.1.41: polypeptide N-acetylgalactosaminyltransferase EC 2.4.1.42: deleted, included in EC 2.4.1.17 EC 2.4.1.43: polygalacturonate 4-α-galacturonosyltransferase EC 2.4.1.44: lipopolysaccharide 3-α-galactosyltransferase EC 2.4.1.45: now included with EC 2.4.1.47, N-acylsphingosine galactosyltransferase EC 2.4.1.46: monogalactosyldiacylglycerol synthase EC 2.4.1.47: N-acylsphingosine galactosyltransferase EC 2.4.1.48: heteroglycan α-mannosyltransferase EC 2.4.1.49: cellodextrin phosphorylase EC 2.4.1.50: procollagen galactosyltransferase EC 2.4.1.51: now covered by EC 2.4.1.101, EC 2.4.1.143, EC 2.4.1.144 and EC 2.4.1.145 EC 2.4.1.52: poly(glycerol-phosphate) α-glucosyltransferase EC 2.4.1.53: poly(ribitol-phosphate) β-glucosyltransferase EC 2.4.1.54: undecaprenyl-phosphate mannosyltransferase EC 2.4.1.55: Now EC 2.7.8.14, CDP-ribitol ribitolphosphotransferase EC 2.4.1.56: lipopolysaccharide N-acetylglucosaminyltransferase EC 2.4.1.57: Newer studies have shown that this is catalysed by two independent activities now covered by EC 2.4.1.345, phosphatidyl-myo-inositol α-mannosyl transferase and EC 2.4.1.346, phosphatidyl-myo-inositol dimannoside synthase EC 2.4.1.58: lipopolysaccharide glucosyltransferase I EC 2.4.1.59: deleted, included in EC 2.4.1.17 EC 2.4.1.60: CDP-abequose:α-D-Man-(1→4)-α-L-Rha-(1→3)-α-D-Gal-PP-Und α-1,3-abequosyltransferase EC 2.4.1.61: deleted, included in EC 2.4.1.17 EC 2.4.1.62: ganglioside galactosyltransferase EC 2.4.1.63: linamarin synthase EC 2.4.1.64: α,α-trehalose phosphorylase EC 2.4.1.65: 3-galactosyl-N-acetylglucosaminide 4-α-L-fucosyltransferase EC 2.4.1.66: procollagen glucosyltransferase EC 2.4.1.67: galactinol—raffinose galactosyltransferase EC 2.4.1.68: glycoprotein 6-α-L-fucosyltransferase EC 2.4.1.69: type 1 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.70: poly(ribitol-phosphate) α-N-acetylglucosaminyltransferase EC 2.4.1.71: arylamine glucosyltransferase EC 2.4.1.72: now EC 2.4.2.24, 1,4-β-D-xylan synthase EC 2.4.1.73: lipopolysaccharide glucosyltransferase II EC 2.4.1.74: glycosaminoglycan galactosyltransferase EC 2.4.1.75: deleted entry, insufficient evidence to conclude that this is a different enzyme from EC 2.4.1.43 EC 2.4.1.76: deleted, included in EC 2.4.1.17 EC 2.4.1.77: deleted, included in EC 2.4.1.17 EC 2.4.1.78: phosphopolyprenol glucosyltransferase EC 2.4.1.79: globotriaosylceramide 3-β-N-acetylgalactosaminyltransferase EC 2.4.1.80: ceramide glucosyltransferase EC 2.4.1.81: flavone 7-O-β-glucosyltransferase EC 2.4.1.82: galactinol—sucrose galactosyltransferase EC 2.4.1.83: dolichyl-phosphate β-D -mannosyltransferase EC 2.4.1.84: deleted, included in EC 2.4.1.17 EC 2.4.1.85: cyanohydrin β-glucosyltransferase EC 2.4.1.86: N-acetyl-β-D-glucosaminide β-(1,3)-galactosyltransferase EC 2.4.1.87: N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.88: globoside α-N-acetylgalactosaminyltransferase EC 2.4.1.89: deleted, included in EC 2.4.1.69, type 1 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.90: N-acetyllactosamine synthase EC 2.4.1.91: flavonol 3-O-glucosyltransferase EC 2.4.1.92: (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase EC 2.4.1.93: Now EC 4.2.2.18, inulin fructotransferase (DFA-III-forming) EC 2.4.1.94: protein N-acetylglucosaminyltransferase EC 2.4.1.95: deleted EC 2.4.1.96: sn-glycerol-3-phosphate 1-galactosyltransferase EC 2.4.1.97: 1,3-β-D-glucan phosphorylase EC 2.4.1.98: deleted, Now included with EC 2.4.1.90, N-acetyllactosamine synthase EC 2.4.1.99: sucrose:sucrose fructosyltransferase EC 2.4.1.100: 2,1-fructan:2,1-fructan 1-fructosyltransferase EC 2.4.1.101: α-1,3-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase EC 2.4.1.102: β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.103: alizarin 2-β-glucosyltransferase EC 2.4.1.104: o-dihydroxycoumarin 7-O-glucosyltransferase EC 2.4.1.105: vitexin β-glucosyltransferase EC 2.4.1.106: isovitexin β-glucosyltransferase EC 2.4.1.107: deleted, now included with EC 2.4.1.17, glucuronosyltransferase EC 2.4.1.108: deleted, now included with EC 2.4.1.17, glucuronosyltransferase EC 2.4.1.109: dolichyl-phosphate-mannose—protein mannosyltransferase EC 2.4.1.110: tRNA-queuosine β-mannosyltransferase EC 2.4.1.111: coniferyl-alcohol glucosyltransferase EC 2.4.1.112: The protein referred to in this entry is now known to be glycogenin so the entry has been incorporated into EC 2.4.1.186, glycogenin glucosyltransferase EC 2.4.1.113: α-1,4-glucan-protein synthase (ADP-forming) EC 2.4.1.114: 2-coumarate O-β-glucosyltransferase EC 2.4.1.115: anthocyanidin 3-O-glucosyltransferase EC 2.4.1.116: cyanidin 3-O-rutinoside 5-O-glucosyltransferase EC 2.4.1.117: dolichyl-phosphate β-glucosyltransferase EC 2.4.1.118: cytokinin 7-β-glucosyltransferase EC 2.4.1.119: transferred to EC 2.4.99.18, dolichyl-diphosphooligosaccharideprotein glycotransferase EC 2.4.1.120: sinapate 1-glucosyltransferase EC 2.4.1.121: indole-3-acetate β-glucosyltransferase EC 2.4.1.122: N-acetylgalactosaminide β-1,3-galactosyltransferase EC 2.4.1.123: inositol 3-α-galactosyltransferase EC 2.4.1.124: Now EC 2.4.1.87, N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.125: sucrose—1,6-α-glucan 3(6)-α-glucosyltransferase EC 2.4.1.126: hydroxycinnamate 4-β-glucosyltransferase EC 2.4.1.127: monoterpenol β-glucosyltransferase EC 2.4.1.128: scopoletin glucosyltransferase EC 2.4.1.129: peptidoglycan glycosyltransferase EC 2.4.1.130: Now covered by EC 2.4.1.258, EC 2.4.1.259, EC 2.4.1.260 and EC 2.4.1.261 EC 2.4.1.131: GDP-Man:Man3GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.132: GDP-Man:Man1GlcNAc2-PP-dolichol α-1,3-mannosyltransferase EC 2.4.1.133: xylosylprotein 4-β-galactosyltransferase EC 2.4.1.134: galactosylxylosylprotein 3-β-galactosyltransferase EC 2.4.1.135: galactosylgalactosylxylosylprotein 3-β-glucuronosyltransferase EC 2.4.1.136: gallate 1-β-glucosyltransferase EC 2.4.1.137: sn-glycerol-3-phosphate 2-α-galactosyltransferase EC 2.4.1.138: mannotetraose 2-α-N-acetylglucosaminyltransferase EC 2.4.1.139: maltose synthase EC 2.4.1.140: alternansucrase EC 2.4.1.141: N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase EC 2.4.1.142: chitobiosyldiphosphodolichol β-mannosyltransferase EC 2.4.1.143: α-1,6-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase EC 2.4.1.144: β-1,4-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.145: α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.146: β-1,3-galactosyl-O-glycosyl-glycoprotein β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.147: acetylgalactosaminyl-O-glycosyl-glycoprotein β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.148: acetylgalactosaminyl-O-glycosyl-glycoprotein β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.149: N-acetyllactosaminide β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.150: N-acetyllactosaminide β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.151: now included with EC 2.4.1.87 N-acetyllactosaminide 3-α-galactosyltransferase EC 2.4.1.152: 4-galactosyl-N-acetylglucosaminide 3-α-L-fucosyltransferase EC 2.4.1.153: UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminyltransferase EC 2.4.1.154: identical to EC 2.4.1.79, globotriaosylceramide 3-β-N-acetylgalactosaminyltransferase EC 2.4.1.155: α-1,6-mannosyl-glycoprotein 6-β-N-acetylglucosaminyltransferase EC 2.4.1.156: indolylacetyl-myo-inositol galactosyltransferase EC 2.4.1.157: 1,2-diacylglycerol 3-glucosyltransferase, now classified as EC 2.4.1.336, monoglucosyldiacylglycerol synthase, and EC 2.4.1.337, 1,2-diacylglycerol 3-α-glucosyltransferase EC 2.4.1.158: 13-hydroxydocosanoate 13-β-glucosyltransferase EC 2.4.1.159: flavonol-3-O-glucoside L-rhamnosyltransferase EC 2.4.1.160: pyridoxine 5′-O-β-D-glucosyltransferase EC 2.4.1.161: oligosaccharide 4-α-D-glucosyltransferase EC 2.4.1.162: aldose β-D-fructosyltransferase EC 2.4.1.163: now included in EC 2.4.1.149, N-acetyllactosaminide β-1,3-N-acetylglucosaminyltransferase EC 2.4.1.164: now included with EC 2.4.1.150, N-acetyllactosaminide β-1,6-N-acetylglucosaminyltransferase EC 2.4.1.165: N-acetylneuraminylgalactosylglucosylceramide β-1,4-N-acetylgalactosaminyltransferase EC 2.4.1.166: raffinose—raffinose α-galactosyltransferase EC 2.4.1.167: sucrose 6F-α-galactosyltransferase EC 2.4.1.168: xyloglucan 4-glucosyltransferase EC 2.4.1.169: now EC 2.4.2.39, xyloglucan 6-xylosyltransferase EC 2.4.1.170: isoflavone 7-O-glucosyltransferase EC 2.4.1.171: methyl-ONN-azoxymethanol β-D-glucosyltransferase EC 2.4.1.172: salicyl-alcohol β-D-glucosyltransferase EC 2.4.1.173: sterol 3β-glucosyltransferase EC 2.4.1.174: glucuronylgalactosylproteoglycan 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.175: glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.176: gibberellin β-D-glucosyltransferase EC 2.4.1.177: cinnamate β-D-glucosyltransferase EC 2.4.1.178: hydroxymandelonitrile glucosyltransferase EC 2.4.1.179: lactosylceramide β-1,3-galactosyltransferase EC 2.4.1.180: lipopolysaccharide N-acetylmannosaminouronosyltransferase EC 2.4.1.181: hydroxyanthraquinone glucosyltransferase EC 2.4.1.182: lipid-A-disaccharide synthase EC 2.4.1.183: α-1,3-glucan synthase EC 2.4.1.184: galactolipid galactosyltransferase EC 2.4.1.185: flavanone 7-O-β-glucosyltransferase EC 2.4.1.186: glycogenin glucosyltransferase EC 2.4.1.187: N-acetylglucosaminyldiphosphoundecaprenol N-acetyl-β-D-mannosaminyltransferase EC 2.4.1.188: N-acetylglucosaminyldiphosphoundecaprenol glucosyltransferase EC 2.4.1.189: uteolin 7-O-glucuronosyltransferase EC 2.4.1.190: luteolin-7-O-glucuronide 2′′-O-glucuronosyltransferase EC 2.4.1.191: luteolin-7-O-diglucuronide 4′-O-glucuronosyltransferase EC 2.4.1.192: nuatigenin 3β-glucosyltransferase EC 2.4.1.193: sarsapogenin 3β-glucosyltransferase EC 2.4.1.194: 4-hydroxybenzoate 4-O-β-D-glucosyltransferase EC 2.4.1.195: N-hydroxythioamide S-β-glucosyltransferase EC 2.4.1.196: nicotinate glucosyltransferase EC 2.4.1.197: high-mannose-oligosaccharide β-1,4-N-acetylglucosaminyltransferase EC 2.4.1.198: phosphatidylinositol N-acetylglucosaminyltransferase EC 2.4.1.199: β-mannosylphosphodecaprenol—mannooligosaccharide 6-mannosyltransferase EC 2.4.1.200: now EC 4.2.2.17, inulin fructotransferase (DFA-I-forming) EC 2.4.1.201: α-1,6-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase EC 2.4.1.202: 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin-3(4H)-one 2-D-glucosyltransferase EC 2.4.1.203: trans-zeatin O-β-D-glucosyltransferase EC 2.4.1.204: now EC 2.4.2.40, zeatin O-β-D-xylosyltransferase EC 2.4.1.205: galactogen 6β-galactosyltransferase EC 2.4.1.206: lactosylceramide 1,3-N-acetyl-β-D-glucosaminyltransferase EC 2.4.1.207: xyloglucan:xyloglucosyl transferase EC 2.4.1.208: diglucosyl diacylglycerol synthase (1,2-linking) EC 2.4.1.209: cis-p-coumarate glucosyltransferase EC 2.4.1.210: limonoid glucosyltransferase EC 2.4.1.211: 1,3-β-galactosyl-N-acetylhexosamine phosphorylase EC 2.4.1.212: hyaluronan synthase EC 2.4.1.213: glucosylglycerol-phosphate synthase EC 2.4.1.214: glycoprotein 3-α-L-fucosyltransferase EC 2.4.1.215: cis-zeatin O-β-D-glucosyltransferase EC 2.4.1.216: trehalose 6-phosphate phosphorylase EC 2.4.1.217: mannosyl-3-phosphoglycerate synthase EC 2.4.1.218: hydroquinone glucosyltransferase EC 2.4.1.219: vomilenine glucosyltransferase EC 2.4.1.220: indoxyl-UDPG glucosyltransferase EC 2.4.1.221: peptide-O-fucosyltransferase EC 2.4.1.222: O-fucosylpeptide 3-β-N-acetylglucosaminyltransferase EC 2.4.1.223: glucuronosyl-galactosyl-proteoglycan 4-α-N-acetylglucosaminyltransferase EC 2.4.1.224: glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-α-N-acetylglucosaminyltransferase EC 2.4.1.225: N-acetylglucosaminyl-proteoglycan 4-β-glucuronosyltransferase EC 2.4.1.226: N-acetylgalactosaminyl-proteoglycan 3-β-glucuronosyltransferase EC 2.4.1.227: undecaprenyldiphospho-muramoylpentapeptide β-N-acetylglucosaminyltransferase EC 2.4.1.228: lactosylceramide 4-α-galactosyltransferase EC 2.4.1.229: [Skp1-protein]-hydroxyproline N-acetylglucosaminyltransferase EC 2.4.1.230: kojibiose phosphorylase EC 2.4.1.231: α,α-trehalose phosphorylase (configuration-retaining) EC 2.4.1.232: initiation-specific α-1,6-mannosyltransferase EC 2.4.1.233: deleted: identical to EC 2.4.1.115, anthocyanidin 3-O-glucosyltransferase EC 2.4.1.234: kaempferol 3-O-galactosyltransferase EC 2.4.1.235: deleted: identical to EC 2.4.1.116, cyanidin 3-O-rutinoside 5-O-glucosyltransferase EC 2.4.1.236: flavanone 7-O-glucoside 2′′-O-β-L-rhamnosyltransferase EC 2.4.1.237: flavonol 7-O-β-glucosyltransferase EC 2.4.1.238: delphinidin 3,5-di-O-glucoside 3′-O-glucosyltransferase EC 2.4.1.239: flavonol-3-O-glucoside glucosyltransferase EC 2.4.1.240: flavonol-3-O-glycoside glucosyltransferase EC 2.4.1.241: flavonol-3-O-glycoside glucosyltransferase EC 2.4.1.242: NDP-glucose—starch glucosyltransferase EC 2.4.1.243: 6G-fructosyltransferase EC 2.4.1.244: N-acetyl-β-glucosaminyl-glycoprotein 4-β-N-acetylgalactosaminyltransferase EC 2.4.1.245: α,α-trehalose synthase EC 2.4.1.246: mannosylfructose-phosphate synthase EC 2.4.1.247: β-D-galactosyl-(1→4)-L-rhamnose phosphorylase EC 2.4.1.248: cycloisomaltooligosaccharide glucanotransferase EC 2.4.1.249: delphinidin 3′,5′-O-glucosyltransferase EC 2.4.1.250: D-inositol-3-phosphate glycosyltransferase EC 2.4.1.251: GlcA-β-(1→2)-D-Man-α-(1→3)-D-Glc-β-(1→4)-D-Glc-α-1-diphospho-ditrans,octacis-undecaprenol 4-β-mannosyltransferase EC 2.4.1.252: GDP-mannose:cellobiosyl-diphosphopolyprenol α-mannosyltransferase EC 2.4.1.253: baicalein 7-O-glucuronosyltransferase EC 2.4.1.254: cyanidin-3-O-glucoside 2′′-O-glucuronosyltransferase EC 2.4.1.255: protein O-GlcNAc transferase EC 2.4.1.256: dolichyl-P-Glc:Glc2Man9GlcNAc2-PP-dolichol α-1,2-glucosyltransferase EC 2.4.1.257: GDP-Man:Man2GlcNAc2-PP-dolichol α-1,6-mannosyltransferase EC 2.4.1.258: dolichyl-P-Man:Man5GlcNAc2-PP-dolichol α-1,3-mannosyltransferase EC 2.4.1.259: dolichyl-P-Man:Man6GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.260: dolichyl-P-Man:Man7GlcNAc2-PP-dolichol α-1,6-mannosyltransferase EC 2.4.1.261: dolichyl-P-Man:Man8GlcNAc2-PP-dolichol α-1,2-mannosyltransferase EC 2.4.1.262: soyasapogenol glucuronosyltransferase EC 2.4.1.263: abscisate β-glucosyltransferase EC 2.4.1.264: D-Man-α-(1→3)-D-Glc-β-(1→4)-DD-Glc-α-1-diphosphoundecaprenol 2-β-glucuronosyltransferase EC 2.4.1.265: olichyl-P-Glc:Glc1Man9GlcNAc2-PP-dolichol α-1,3-glucosyltransferase EC 2.4.1.266: glucosyl-3-phosphoglycerate synthase EC 2.4.1.267: dolichyl-P-Glc:Man9GlcNAc2-PP-dolichol α-1,3-glucosyltransferase EC 2.4.1.268: glucosylglycerate synthase EC 2.4.1.269: mannosylglycerate synthase EC 2.4.1.270: mannosylglucosyl-3-phosphoglycerate synthase EC 2.4.1.271: crocetin glucosyltransferase EC 2.4.1.272: soyasapogenol B glucuronide galactosyltransferase EC 2.4.1.273: soyasaponin III rhamnosyltransferase EC 2.4.1.274: glucosylceramide β-1,4-galactosyltransferase EC 2.4.1.275: neolactotriaosylceramide β-1,4-galactosyltransferase EC 2.4.1.276: zeaxanthin glucosyltransferase EC 2.4.1.277: glycosyltransferase DesVII EC 2.4.1.278: desosaminyl transferase EryCIII EC 2.4.1.279: nigerose phosphorylase EC 2.4.1.280: N,N′-diacetylchitobiose phosphorylase EC 2.4.1.281: 4-O-β-D-mannosyl-D-glucose phosphorylase EC 2.4.1.282: 3-O-α-D-glucosyl-L-rhamnose phosphorylase EC 2.4.1.283: 2-deoxystreptamine N-acetyl-D-glucosaminyltransferase EC 2.4.1.284: 2-deoxystreptamine glucosyltransferase EC 2.4.1.285: UDP-GlcNAc:ribostamycin N-acetylglucosaminyltransferase EC 2.4.1.286: chalcone 4′-O-glucosyltransferase EC 2.4.1.287: rhamnopyranosyl-N-acetylglucosaminyl-diphospho-decaprenol β-1,4/1,5-galactofuranosyltransferase EC 2.4.1.288: galactofuranosylgalactofuranosylrhamnosyl-N-acetylglucosaminyl-diphospho-decaprenol β-1,5/1,6-galactofuranosyltransferase EC 2.4.1.289: N-acetylglucosaminyl-diphospho-decaprenol L-rhamnosyltransferase EC 2.4.1.290: N,N′-diacetylbacillosaminyl-diphospho-undecaprenol α-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.291: N-acetylgalactosamine-N,N′-diacetylbacillosaminyl-diphospho-undecaprenol 4-α-N-acetylgalactosaminyltransferase EC 2.4.1.292: GalNAc-α-(1→4)-GalNAc-α-(1→3)-diNAcBac-PP-undecaprenol α-1,4-N-acetyl-D-galactosaminyltransferase EC 2.4.1.293: GalNAc5-diNAcBac-PP-undecaprenol β-1,3-glucosyltransferase EC 2.4.1.294: cyanidin 3-O-galactosyltransferase EC 2.4.1.295: anthocyanin 3-O-sambubioside 5-O-glucosyltransferase EC 2.4.1.296: anthocyanidin 3-O-coumaroylrutinoside 5-O-glucosyltransferase EC 2.4.1.297: anthocyanidin 3-O-glucoside 2′′-O-glucosyltransferase EC 2.4.1.298: anthocyanidin 3-O-glucoside 5-O-glucosyltransferase EC 2.4.1.299: cyanidin 3-O-glucoside 5-O-glucosyltransferase (acyl-glucose) EC 2.4.1.300: cyanidin 3-O-glucoside 7-O-glucosyltransferase (acyl-glucose) EC 2.4.1.301: 2′-deamino-2′-hydroxyneamine 1-α-D-kanosaminyltransferase EC 2.4.1.302: L-demethylnoviosyl transferase EC 2.4.1.303: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol β-1,3-galactosyltransferase EC 2.4.1.304: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol β-1,4-galactosyltransferase EC 2.4.1.305: UDP-Glc:α-D-GlcNAc-glucosaminyl-diphosphoundecaprenol β-1,3-glucosyltransferase EC 2.4.1.306: UDP-GalNAc:α-D-GalNAc-diphosphoundecaprenol α-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.307: UDP-Gal:α-D-GalNAc-1,3-α-D-GalNAc-diphosphoundecaprenol β-1,3-galactosyltransferase. Now included in EC 2.4.1.122, N-acetylgalactosaminide β-1,3-galactosyltransferase EC 2.4.1.308: GDP-Fuc:β-D-Gal-1,3-α-D-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,2-fucosyltransferase EC 2.4.1.309: UDP-Gal:α-L-Fuc-1,2-β-Gal-1,3-α-GalNAc-1,3-α-GalNAc-diphosphoundecaprenol α-1,3-galactosyltransferase EC 2.4.1.310: vancomycin aglycone glucosyltransferase EC 2.4.1.311: chloroorienticin B synthase EC 2.4.1.312: protein O-mannose β-1,4-N-acetylglucosaminyltransferase EC 2.4.1.313: protein O-mannose β-1,3-N-acetylgalactosaminyltransferase EC 2.4.1.314: ginsenoside Rd glucosyltransferase EC 2.4.1.315: diglucosyl diacylglycerol synthase (1,6-linking) EC 2.4.1.316: tylactone mycaminosyltransferase EC 2.4.1.317: O-mycaminosyltylonolide 6-deoxyallosyltransferase EC 2.4.1.318: demethyllactenocin mycarosyltransferase EC 2.4.1.319: β-1,4-mannooligosaccharide phosphorylase EC 2.4.1.320: 1,4-β-mannosyl-N-acetylglucosamine phosphorylase EC 2.4.1.321: cellobionic acid phosphorylase EC 2.4.1.322: devancosaminyl-vancomycin vancosaminetransferase EC 2.4.1.323: 7-deoxyloganetic acid glucosyltransferase EC 2.4.1.324: 7-deoxyloganetin glucosyltransferase EC 2.4.1.325: TDP-N-acetylfucosamine:lipid II N-acetylfucosaminyltransferase EC 2.4.1.326: aklavinone 7-L-rhodosaminyltransferase EC 2.4.1.327: aclacinomycin-T 2-deoxy-L-fucose transferase EC 2.4.1.328: erythronolide mycarosyltransferase EC 2.4.1.329: sucrose 6F-phosphate phosphorylase EC 2.4.1.330: β-D-glucosyl crocetin β-1,6-glucosyltransferase EC 2.4.1.331: 8-demethyltetracenomycin C L-rhamnosyltransferase EC 2.4.1.332: 1,2-α-glucosylglycerol phosphorylase EC 2.4.1.333: 1,2-β-oligoglucan phosphorylase EC 2.4.1.334: 1,3-α-oligoglucan phosphorylase EC 2.4.1.335: dolichyl N-acetyl-α-D-glucosaminyl phosphate 3-β-D-2,3-diacetamido-2,3-dideoxy-β-D-glucuronosyltransferase EC 2.4.1.336: monoglucosyldiacylglycerol synthase EC 2.4.1.337: 1,2-diacylglycerol 3-α-glucosyltransferase EC 2.4.1.338: validoxylamine A glucosyltransferase EC 2.4.1.339: β-1,2-mannobiose phosphorylase EC 2.4.1.340: 1,2-β-oligomannan phosphorylase EC 2.4.1.341: α-1,2-colitosyltransferase EC 2.4.1.342: α-maltose-1-phosphate synthase EC 2.4.1.343: UDP-Gal:α-D-GlcNAc-diphosphoundecaprenol α-1,3-galactosyltransferase EC 2.4.1.344: type 2 galactoside α-(1,2)-fucosyltransferase EC 2.4.1.345: phosphatidyl-myo-inositol α-mannosyltransferase EC 2.4.1.346: phosphatidyl-myo-inositol dimannoside synthase EC 2.4.1.347: α,α-trehalose-phosphate synthase (ADP-forming) EC 2.4.1.348: N-acetyl-α-D-glucosaminyl-diphospho-ditrans,octacis-undecaprenol 3-α-mannosyltransferase EC 2.4.1.349: mannosyl-N-acetyl-α-D-glucosaminyl-diphospho-ditrans,octacis-undecaprenol 3-α-mannosyltransferase EC 2.4.1.350: mogroside IE synthase EC 2.4.1.351: rhamnogalacturonan I rhamnosyltransferase EC 2.4.1.352: glucosylglycerate phosphorylase EC 2.4.1.353: sordaricin 6-deoxyaltrosyltransferase EC 2.4.1.354: (R)-mandelonitrile β-glucosyltransferase EC 2.4.1.355: poly(ribitol-phosphate) β-N-acetylglucosaminyltransferase EC 2.4.1.356: glucosyl-dolichyl phosphate glucuronosyltransferase EC 2.4.1.357: phlorizin synthase EC 2.4.1.358: acylphloroglucinol glucosyltransferase EC 2.4.1.359: glucosylglycerol phosphorylase (configuration-retaining) EC 2.4.1.360: 2-hydroxyflavanone C-glucosyltransferase EC 2.4.1.361: GDP-mannose:di-myo-inositol-1,3′-phosphate β-1,2-mannosyltransferase EC 2.4.1.362: α-(1→3) branching sucrase EC 2.4.1.363: ginsenoside 20-O-glucosyltransferase EC 2.4.1.364: protopanaxadiol-type ginsenoside 3-O-glucosyltransferase EC 2.4.1.365: protopanaxadiol-type ginsenoside-3-O-glucoside 2′′-O-glucosyltransferase EC 2.4.1.366: ginsenoside F1 6-O-glucosyltransferase EC 2.4.1.367: ginsenoside 6-O-glucosyltransferase EC 2.4.1.368: oleanolate 3-O-glucosyltransferase EC 2.4.1.369: enterobactin C-glucosyltransferase EC 2.4.1.370: inositol phosphorylceramide mannosyltransferase EC 2.4.1.371: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol 2,3-α-mannosylpolymerase EC 2.4.1.372: mutansucrase EC 2.4.1.373: α-(1→2) branching sucrase EC 2.4.1.374: β-1,2-mannooligosaccharide synthase EC 2.4.1.375: rhamnogalacturonan I galactosyltransferase EC 2.4.1.376: EGF-domain serine glucosyltransferase EC 2.4.1.377: dTDP-Rha:α-D-Gal-diphosphoundecaprenol α-1,3-rhamnosyltransferase EC 2.4.1.378: GDP-mannose:α-L-Rha-(1→3)-α-D-Gal-PP-Und α-1,4-mannosyltransferase EC 2.4.1.379: GDP-Man:α-D-Gal-diphosphoundecaprenol α-1,3-mannosyltransferase EC 2.4.1.380: GDP-Man:α-D-Man-(1→3)-α-D-Gal diphosphoundecaprenol α-1,2-mannosyltransferase EC 2.4.1.381: dTDP-Rha:α-D-Man-(1→3)-α-D-Gal diphosphoundecaprenol α-1,2-rhamnosyltransferase EC 2.4.1.382: CDP-abequose:α-L-Rha2OAc-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und α-1,3-abequosyltransferase EC 2.4.1.383: GDP-Man:α-L-Rha-(1→3)-α-D-Gal-PP-Und β-1,4-mannosyltransferase EC 2.4.1.384: NDP-glycosyltransferase
== NMR spectroscopy on large proteins == Traditionally, nuclear magnetic resonance spectroscopy has been limited to relatively small proteins or protein domains. This is in part caused by problems resolving overlapping peaks in larger proteins, but this has been alleviated by the introduction of isotope labelling and multidimensional experiments. Another more serious problem is the fact that in large proteins the magnetization relaxes faster, which means there is less time to detect the signal. This in turn causes the peaks to become broader and weaker, and eventually disappear. Two techniques have been introduced to attenuate the relaxation: transverse relaxation optimized spectroscopy (TROSY) and deuteration of proteins. By using these techniques it has been possible to study proteins in complex with the 900 kDa chaperone GroES-GroEL.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.